Can Tumor Organoids Make Drug Discovery More Predictive?

How patient-derived tumor organoids, high-content screening, and advanced analytical readouts could provide more predictive models for cancer drug discoveryw

September 3, 2026
8 min

The Analytical Scientist

Original Source(s)

The Analytical Scientist

Can Tumor Organoids Make Drug Discovery More Predictive?

September 3, 2026

Related Content

Nature Medicine

Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

by Benjamin H. Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, David Abramson, Veronica Rotemberg, Steven De Munck, Erwin Pannecoucke, Sydney X. Lu, Alessandro Pastore, Akihide Yoshimi, Diana Mandelker, Ozge Ceyhan-Birsoy, Gary A. Ulaner, Michael Walsh, Mariko Yabe, Kseniya Petrova-Drus, Maria E. Arcila, Marc Ladanyi, David B. Solit, Michael F. Berger, David M. Hyman, Mario E. Lacouture, Caroline Erickson, Ruth Saganty, Michelle Ki, Ira J. Dunkel, Vicente Santa-María López, Jaume Mora, Julien Haroche, Jean-Francois Emile, Olivier Decaux, Frederic Geissmann, Savvas N. Savvides, Alexander Drilon, Eli L. Diamond, Omar Abdel-Wahab
September 1, 2026

Frontiers In Immunology

Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis

by Dandan Liang, Qinghua Liu, Min Liu, Yi Li
September 1, 2026

Frontiers In Oncology

Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report

by Yi Bao, Lei Zhang, Fenfen Jiang, Juanfen Mo
September 1, 2026